<DOC>
	<DOCNO>NCT01143272</DOCNO>
	<brief_summary>When patient hospital receive antibiotic often develop diarrhoea . The consequence may grave patient . Thus far , preventive measure available . The investigator hypothesize apathogenic yeast Saccharomyces boulardii , administer addition antibiotic , may prevent episode diarrhoea may lead less pronounced diarrhoea . To test hypothesis , investigator carry clinical trial 1520 adult patient several hospital .</brief_summary>
	<brief_title>Probiotic Saccharomyces Boulardii Prevention Antibiotic-associated Diarrhoea</brief_title>
	<detailed_description>Antibiotic-associated diarrhoea ( AAD ) frequent condition hospitalise patient receive antibiotic treatment . The true Clostridium difficile-associated diarrhoea ( CDAD ) even grave consequence increase morbidity mortality . The development evaluation preventive strategy one key public health challenge . In absence clinically evaluate alternative , probiotic suggest beneficial prevention AAD CDAD . However , data far inconclusive recently publish meta-analyses strongly recommend large state-of-the-art clinical trial probiotic substance prevention AAD CDAD . Since efficacy , side-effects mode action different probiotic bacteria yeast strain specific , benefit risk generalise . The non-pathogenic yeast Saccharomyces cerevisiae var . boulardii ( Sac . boulardii ) consider promising probiotic substance prevention AAD CDAD . We carry randomise , placebo control , double blind multicentre clinical trial evaluate Sac . boulardii indication prevention AAD CDAD 1520 adult , hospitalise patient .</detailed_description>
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>Antibiotics , Antitubercular</mesh_term>
	<criteria>adult patient ( ≥ 18 year ) patient hospitalize patient receives systemic antibiotic treatment patient contractually capable patient able follow study procedure inform consent patient allergy yeast and/or Perenterol® forte und/oder placebo contain Saccharomyces cerevisiae HANSEN CBS 5926 , lactosemonohydrate , magnesium stearate , gelatine , sodium dodecyl sulfate , titan dioxide , microcrystalline cellulose . central venous catheter immunosuppression diarrhoea and/or chronic diarrhoea regular intake Perenterol® , Perenterol® forte oder Yomogi® last seven day start study systemic antimycotic treatment systemic antibiotic treatment within last 6 week protection conception , pregnancy , lactation simultaneous participation clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>antibiotic</keyword>
	<keyword>associate</keyword>
	<keyword>diarrhoea</keyword>
	<keyword>saccharomyces boulardii</keyword>
	<keyword>Antibiotic-associated diarrhoea ( AAD )</keyword>
	<keyword>Clostridium difficile-associated-diarrhoea ( CDAD )</keyword>
</DOC>